September 19, 2016—The New York Times and investigative journalists at The Center for Public Integrity have both published recent exposés about how drug companies co-opt patient-advocacy and civic groups to do their bidding with lavish donations. The exposés are timely, as some disease-awareness and concerned-citizens groups are ramping up efforts to get Congress to “reform” the 340B drug discount program into oblivion.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)